Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Anhui Medical UniversityNo recent work listed

Wei Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0000-7266-2191; OpenAlex author ID A5108048725. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper

Papers 3

  1. PSMC2 is a Novel Prognostic Biomarker and Predicts Immunotherapeutic Responses: From Pancreatic Cancer to Pan-Cancer. Co-author DOI 10.2147/pgpm.s418533↗
  2. Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a re… Co-author DOI 10.21037/atm-22-544↗
  3. PSMC2 is Up-regulated in Pancreatic Cancer and Promotes Cancer Cell Proliferation and Inhibits Apoptosis. Co-author DOI 10.7150/jca.27616↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Junli Ding · 2 shared papers, 2019–2023 · strength 0.32
  2. Junying Xu · 1 shared paper, 2023 · strength 0.19
  3. Jie Mei · 1 shared paper, 2023 · strength 0.19
  4. Hongyang Wu · 1 shared paper, 2022 · strength 0.16
  5. Congjun Zhang · 1 shared paper, 2022 · strength 0.16
  6. Jing Qin · 1 shared paper, 2019 · strength 0.12
  7. Fangmei An · 1 shared paper, 2019 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.